- Home
- MGF vs RAPT Comparison
MGF vs RAPT Comparison
Compare MGF & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGF
- RAPT
- Stock Information
- Founded
- MGF 1987
- RAPT 2015
- Country
- MGF United States
- RAPT United States
- Employees
- MGF N/A
- RAPT N/A
- Industry
- MGF Trusts Except Educational Religious and Charitable
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- MGF Finance
- RAPT Health Care
- Exchange
- MGF Nasdaq
- RAPT Nasdaq
- Market Cap
- MGF 104.3M
- RAPT 106.8M
- IPO Year
- MGF N/A
- RAPT 2019
- Fundamental
- Price
- MGF $3.27
- RAPT $1.97
- Analyst Decision
- MGF
- RAPT Hold
- Analyst Count
- MGF 0
- RAPT 9
- Target Price
- MGF N/A
- RAPT $7.25
- AVG Volume (30 Days)
- MGF 104.4K
- RAPT 257.7K
- Earning Date
- MGF 01-01-0001
- RAPT 11-11-2024
- Dividend Yield
- MGF 7.64%
- RAPT N/A
- EPS Growth
- MGF N/A
- RAPT N/A
- EPS
- MGF N/A
- RAPT N/A
- Revenue
- MGF N/A
- RAPT N/A
- Revenue This Year
- MGF N/A
- RAPT N/A
- Revenue Next Year
- MGF N/A
- RAPT N/A
- P/E Ratio
- MGF N/A
- RAPT N/A
- Revenue Growth
- MGF N/A
- RAPT N/A
- 52 Week Low
- MGF $2.91
- RAPT $1.77
- 52 Week High
- MGF $3.46
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- MGF 67.03
- RAPT 35.69
- Support Level
- MGF $3.17
- RAPT $1.77
- Resistance Level
- MGF $3.27
- RAPT $2.10
- Average True Range (ATR)
- MGF 0.02
- RAPT 0.18
- MACD
- MGF 0.00
- RAPT 0.01
- Stochastic Oscillator
- MGF 83.33
- RAPT 22.57
About MGF MFS Government Markets Income Trust
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.